GlassScriptPhysician profile
Alberto Diaz
NPI 1659879344
$4,104.78
in general payments reported to CMS, 2019-2025
26 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,069 · 2022: $739 · 2023: $99.00 · 2024: $26.19 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.65 |
| Education | $197.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $504.41 | 2021-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.34 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $442.92 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $419.41 | 2021-2025 | Andexxa, Farxiga, Wainua |
| Amgen INC. | $338.93 | 2021-2025 | Repatha |
| Actelion Pharmaceuticals US, INC. | $275.88 | 2025 | Uptravi, Opsumit |
| Tactile Systems Technology INC | $254.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $243.70 | 2021-2025 | |
| Astellas Pharma US INC | $192.96 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $189.56 | 2021-2025 | |
| Pfizer INC. | $122.78 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.85 | 2025 | Camzyos |
| Merck Sharp & Dohme LLC | $116.87 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $79.72 | 2021-2024 | Optimizer |
| Amarin Pharma, INC. | $73.44 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $70.71 | 2021-2022 | |
| Boston Scientific Corporation | $29.42 | 2022 | |
| Alnylam Pharmaceuticals INC. | $28.17 | 2025 | Amvuttra |
| Bardy Diagnostics, INC. | $26.00 | 2021 | |
| Esperion Therapeutics, INC. | $24.94 | 2021 | |
| Medtronic, INC. | $23.76 | 2022 | |
| Cvrx, INC. | $21.81 | 2022 | |
| Lundbeck LLC | $15.86 | 2021 | |
| G Medical Diagnostic Services, INC. | $14.28 | 2022 | |
| Altathera Pharmaceuticals LLC | $13.13 | 2025 | Sotalol Hydrochloride |
| Arbor Pharmaceuticals, INC. | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.